Literature DB >> 11747625

Mapping of IFN-beta epitopes important for receptor binding and biologic activation: comparison of results achieved using antibody-based methods and alanine substitution mutagenesis.

L Runkel1, C De Dios, M Karpusas, D Baker, Z Li, M Zafari, M Betzenhauser, C Muldowney, S Miller, P N Redlich, S E Grossberg, A Whitty, P S Hochman.   

Abstract

The epitopes important for receptor binding and activation of human interferon-beta1a (IFN-beta1a) were mapped with monoclonal antibodies (mAb), grouped on the basis of their specificity and ability to neutralize biologic activity, and alanine scanning mutagenesis (ASM). The binding properties of nine mAb were defined, using ASM-IFN-beta mutants having alanine substituted at targeted, surface-exposed residues. The results were correlated with the mAb neutralizing potency. Of six mAb that bound either at or adjacent to the IFNAR-2 receptor chain binding site defined by the ASM epitopes, only three had measurable neutralizing activity. Two of these inhibited IFN-beta/IFNAR-2 complex formation, suggesting that steric hindrance of receptor binding constitutes their mechanism of neutralization. However, two mAb that bound to sites remote from the IFNAR-2 binding site on IFN-beta also inhibited IFN-beta/IFNAR-2 complex formation and demonstrated potent neutralizing activity. Thus, neutralizing mAb may employ mechanisms other than steric blockade to inhibit directly the binding of receptor by cytokine, limiting their usefulness as tools to define precise receptor-ligand interaction sites.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11747625     DOI: 10.1089/107999001753289541

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  7 in total

1.  Regulation of Th1/Th17 cytokines and IDO gene expression by inhibition of calpain in PBMCs from MS patients.

Authors:  Amena W Smith; Bently P Doonan; William R Tyor; Nada Abou-Fayssal; Azizul Haque; Naren L Banik
Journal:  J Neuroimmunol       Date:  2010-11-13       Impact factor: 3.478

2.  Importance of residue 13 and the C-terminus for the structure and activity of the antimicrobial peptide aurein 2.2.

Authors:  John T J Cheng; John D Hale; Jason Kindrachuk; Håvard Jenssen; Havard Jessen; Melissa Elliott; Robert E W Hancock; Suzana K Straus
Journal:  Biophys J       Date:  2010-11-03       Impact factor: 4.033

3.  The impact of neutralizing antibodies on the risk of disease worsening in interferon β-treated relapsing multiple sclerosis: a 5 year post-marketing study.

Authors:  D Paolicelli; M D'Onghia; F Pellegrini; V Direnzo; P Iaffaldano; V Lavolpe; M Trojano
Journal:  J Neurol       Date:  2013-02-17       Impact factor: 4.849

4.  The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression.

Authors:  Josiane Ragimbeau; Elisabetta Dondi; Andrés Alcover; Pierre Eid; Gilles Uzé; Sandra Pellegrini
Journal:  EMBO J       Date:  2003-02-03       Impact factor: 11.598

5.  MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity.

Authors:  Andrew Pachner; Kavitha Narayan; Nicholson Price; Marie Hurd; Donna Dail
Journal:  Mol Diagn       Date:  2003

6.  The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy.

Authors:  Damiano Paolicelli; Sergio Iannazzo; Laura Santoni; Antonio Iaffaldano; Valentina Di Lecce; Alessia Manni; Vito Lavolpe; Carla Tortorella; Mariangela D'Onghia; Vita Direnzo; Elisa Puma; Maria Trojano
Journal:  PLoS One       Date:  2016-07-08       Impact factor: 3.240

Review 7.  The yin and yang of viruses and interferons.

Authors:  Ben X Wang; Eleanor N Fish
Journal:  Trends Immunol       Date:  2012-02-07       Impact factor: 16.687

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.